Reviva Pharmaceuticals Inc Appoints Three New Board Members

SANTA CLARA, Calif.--(BUSINESS WIRE)--Reviva Pharmaceuticals, Inc., (Reviva), a privately held drug discovery and development company, announced today that it has appointed life sciences industry experts, Brian G. Atwood, Sarvajna Dwivedi and Peder K. Jensen to its Board of Directors. "We are extremely pleased to welcome Mr. Atwood, Dr. Jensen and Dr. Dwivedi to the Board," said Laxminarayan Bhat, Founder, President and Chief Executive Officer of Reviva.

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.